These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23129731)

  • 1. Urine drug testing of chronic pain patients. V. Prevalence of propoxyphene following its withdrawal from the United States market.
    Puet B; DePriest A; Knight J; Heltsley R; Black DL; Caplan YH; Cone EJ
    J Anal Toxicol; 2013; 37(1):1-4. PubMed ID: 23129731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A trend analysis of laboratory positive propoxyphene workplace urine drug screens before and after the product recall.
    Price J
    J Addict Med; 2015; 9(2):136-8. PubMed ID: 25622125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States' market: An analysis from the state of Florida.
    Delcher C; Chen G; Wang Y; Slavova S; Goldberger BA
    Forensic Sci Int; 2017 Nov; 280():228-232. PubMed ID: 29080523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unstable propoxyphene metabolite excreted in human urine is detected by liquid chromatography-tandem mass spectrometry.
    Crews B; Mikel C; Latyshev S; West R; Pesce A
    J Anal Toxicol; 2009 Sep; 33(7):379-83. PubMed ID: 19796508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens.
    Heltsley R; Depriest A; Black DL; Crouch DJ; Robert T; Marshall L; Meadors VM; Caplan YH; Cone EJ
    J Anal Toxicol; 2012 Mar; 36(2):75-80. PubMed ID: 22337775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of oral fluid in compliance monitoring of opioid medications.
    Conermann T; Gosalia AR; Kabazie AJ; Moore C; Miller K; Fetsch M; Irvan D
    Pain Physician; 2014; 17(1):63-70. PubMed ID: 24452646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urine drug testing for pain management.
    Magnani B; Kwong T
    Clin Lab Med; 2012 Sep; 32(3):379-90. PubMed ID: 22939297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gas chromatographic quantitation of dextropropoxyphene and norpropoxyphene in urine after solid-phase extraction.
    Amalfitano G; Bessard J; Vincent F; Eysseric H; Bessard G
    J Anal Toxicol; 1996; 20(7):547-54. PubMed ID: 8934304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urine drug testing of chronic pain patients. III. Normetabolites as biomarkers of synthetic opioid use.
    Depriest A; Heltsley R; Black DL; Cawthon B; Robert T; Moser F; Caplan YH; Cone EJ
    J Anal Toxicol; 2010 Oct; 34(8):444-9. PubMed ID: 21819788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative evaluation of the accuracy of immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing (UDT) opioids and illicit drugs in chronic pain patients.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(2):175-87. PubMed ID: 21412372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events.
    Jeffery MM; Morden NE; Larochelle M; Shah ND; Hooten WM; Meara E
    Med Care; 2020 Jan; 58(1):4-12. PubMed ID: 31651743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Food and Drug Administration recommends against the continued use of propoxyphene.
    Food And Drug Administration Public Health Service U S Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2011; 25(1):80-2. PubMed ID: 21426228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Triage PPY on-site testing device for the detection of dextropropoxyphene in urine.
    Poklis A; Poklis JL; Tarnai LD; Backer RC
    J Anal Toxicol; 2004 Sep; 28(6):485-8. PubMed ID: 15516300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of the accuracy of benzodiazepine testing in chronic pain patients utilizing immunoassay with liquid chromatography tandem mass spectrometry (LC/MS/MS) of urine drug testing.
    Manchikanti L; Malla Y; Wargo BW; Fellows B
    Pain Physician; 2011; 14(3):259-70. PubMed ID: 21587329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved detection of opioid use in chronic pain patients through monitoring of opioid glucuronides in urine.
    Dickerson JA; Laha TJ; Pagano MB; O'Donnell BR; Hoofnagle AN
    J Anal Toxicol; 2012 Oct; 36(8):541-7. PubMed ID: 22833646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of propoxyphene withdrawal on opioid use in veterans.
    Hayes CJ; Hudson TJ; Phillips MM; Bursac Z; Williams JS; Austin MA; Edlund MJ; Martin BC
    Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1180-8. PubMed ID: 26248742
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA/DEA/PDMP/UDT: alphabet soup or sensible and integrated risk management?
    Passik SD; Kirsh KL; Twillman RK
    J Opioid Manag; 2015; 11(1):77-81. PubMed ID: 25750168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.